SKG0201 Injection

GENETIC2 trials

Sponsors

Kun Sun, Lanyue Biotech (Hangzhou) Co., Ltd.

Conditions

Spinal Muscular Atrophy 1

Phase 1

A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I

RecruitingNCT07554924

Lanyue Biotech (Hangzhou) Co., Ltd.Spinal Muscular Atrophy 1

Start: 2026-07-15End: 2029-05-25Target: 11Updated: 2026-08-26

Unknown Phase

A Clinical Study Evaluating the Safety and Efficacy of SKG0201 Injection in Patients With Spinal Muscular Atrophy Type 1

Active, not recruitingNCT06191354

Kun SunSpinal Muscular Atrophy 1

Start: 2023-06-25End: 2025-12-31Target: 12Updated: 2025-11-21